Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of
Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis
and pMMR/MSS status.